Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...
Merck MRK announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company ...
Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...
BioNTech SE (BNTX) has released an update. BioNTech SE is entering a new phase of growth, focusing on expanding its oncology ...
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid ...
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback